Skip to main content
Our trust values
University Hospitals Dorset NHS Foundation Trust

University Hospitals Dorset contribute to international Covid-19 therapy evaluation trials 
 

Research teams at University Hospitals Dorset recruited 75 participants for the REGEN-COV arm of the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, which is the first large enough to determine definitively whether treatment developed by Regeneron reduces mortality in patients hospitalised with severe Covid-19.
 
The trial has demonstrated that the investigational antibody combination reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.  

Dr Martin Schuster Bruce, UHD consultant in critical care and anaesthesia explains:‘We are really excited to hear about the release of the RECOVERY trial data for REGEN-COV, which is an antibody cocktail against COVID -19. The trial showed that in hospitalised patients with severe COVID-19 , who have not mounted a natural antibody response, this cocktail of antibodies saves lives. I am immensely proud of the RECOVERY trial and UHD’s involvement in this world class medical research that has resulted in millions of lives saved’. 

Professor Nick Lemoine, Medical Director at the National Institute for Health Research (NIHR) Clinical Research Network said ‘It is fantastic news that the RECOVERY trial has provided evidence to establish another lifesaving treatment against COVID-19 through this monoclonal antiviral antibody combination. The incredible impact the trial continues to have is testament to the scientists and healthcare professionals – but equally the tens of thousands of patients who have taken part. We sincerely want to thank every single one of them for their contribution.’
recovery logo chosen mar 2020
Back to top of page